2007-2020年瑞典炎症性肠病医疗费用持续增加
该研究基于瑞典全国登记数据,链接所有克罗恩病(CD)和溃疡性结肠炎(UC)患者与按性别、出生年份、医疗区域和教育匹配的参照人群,评估2007-2020年包括生产力损失在内的年均费用(以2020年通胀调整后的欧元计)。结果显示,工作年龄(18-64岁)患者绝对年均社会费用CD下降17%(参照人群下降24%)、UC下降20%(参照人群下降27%),超额费用从以生产力损失为主转向以直接医疗费用为主,儿童和老年患者绝对费用与超额费用均增加,TNF抑制剂/靶向治疗费用CD增加274%、UC增加638%,治疗比例CD从5%升至26%、UC从1%升至10%。
要点
- 工作年龄患者绝对年均社会费用CD下降17%、UC下降20%,但参照人群降幅更大(CD降24%、UC降27%)。
- 超额费用构成从以生产力损失为主转向以直接医疗费用为主,儿童和老年患者绝对及超额费用均增加。
- TNF抑制剂/靶向治疗费用CD增加274%、UC增加638%,治疗比例CD从5%升至26%、UC从1%升至10%。
核心结论
- 2007-2020年间超额费用从生产力损失转向直接医疗费用,即患者病假补偿减少而社会药品支出增加。
- 药品费用增长既源于TNF抑制剂使用扩大,也源于新型靶向治疗的高费用。
研究设计与样本
- 基于瑞典全国登记数据的纵向研究,链接所有CD或UC患者与按性别、出生年份、医疗区域和教育匹配的参照人群。
- 评估2007-2020年住院、门诊就诊、药物、病假和残疾抚恤金的年均费用(以2020年通胀调整后的欧元计),超额费用定义为患者与匹配对照者的均值差。
主要发现
- 工作年龄(18-64岁)患者绝对年均社会费用CD下降17%(参照人群下降24%)、UC下降20%(参照人群下降27%),源于病假和残疾费用下降,与更严格的病假规定相关。
- 2007年超额费用以生产力损失为主,2020年超额费用以医疗费用为主。
- 儿童和老年患者绝对费用与超额费用均增加。
- TNF抑制剂/靶向治疗总费用CD增加274%、UC增加638%,治疗比例CD从5%升至26%、UC从1%升至10%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel disease has been linked to increasing healthcare costs, but longitudinal data on other societal costs are scarce. AIM: To assess costs, including productivity losses, in patients with prevalent Crohn's disease (CD) or ulcerative colitis (UC) in Sweden between 2007 and 2020. METHODS: We linked data from national registers on all patients with CD or UC and a matched (sex, birthyear, healthcare region and education) reference population. We assessed mean costs/year in Euros, inflation-adjusted to 2020, for hospitalisations, out-patient visits, medications, sick leave and disability pension. We defined excess costs as the mean difference between patients and matched comparators. RESULTS: Between 2007 and 2020, absolute mean annual societal costs in working-age (18-64 years) individuals decreased by 17% in CD (-24% in the comparators) and by 20% in UC (-27% in comparators), due to decreasing costs from sick leave and disability, a consequence of stricter sick leave regulations. Excess costs in 2007 were dominated by productivity losses. In 2020, excess costs were mostly healthcare costs. Absolute and excess costs increased in paediatric and elderly patients. Overall, costs for TNF inhibitors/targeted therapies increased by 274% in CD and 638% in UC, and the proportion treated increased from 5% to 26% in CD, and from 1% to 10% in UC. CONCLUSION: Between 2007 and 2020, excess costs shifted from productivity losses to direct healthcare costs; that is, the patients' compensation for sickness absence decreased, while society increased its spending on medications. Medication costs were driven both by expanding use of TNF inhibitors and by high costs for newer targeted therapies.
引用
- Everhov ÅH, Söderling J, Befrits G, et al. Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden. Aliment Pharmacol Ther. 2023. PMID: 37594381. doi:10.1111/apt.17675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。